Current Report Filing (8-k)
October 02 2020 - 4:06PM
Edgar (US Regulatory)
0001551152
false
Common Stock, $0.01 Par Value
ABBV
0001551152
2020-10-02
2020-10-02
0001551152
us-gaap:CommonStockMember
exch:XNYS
2020-10-02
2020-10-02
0001551152
exch:XCHI
us-gaap:CommonStockMember
2020-10-02
2020-10-02
0001551152
abbv:Sec1.375SeniorNotesDue2024Member
exch:XNYS
2020-10-02
2020-10-02
0001551152
abbv:Sec0.750SeniorNotesDue2027Member
exch:XNYS
2020-10-02
2020-10-02
0001551152
abbv:Sec2.125SeniorNotesDue2028Member
exch:XNYS
2020-10-02
2020-10-02
0001551152
abbv:Sec1.250SeniorNotesDue2031Member
exch:XNYS
2020-10-02
2020-10-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): October 2, 2020
ABBVIE INC.
(Exact Name of Registrant as Specified
in its Charter)
Delaware
|
|
001-35565
|
|
32-0375147
|
(State or other Jurisdiction
of Incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.)
|
1 North Waukegan Road
North Chicago, Illinois 60064-6400
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (847) 932-7900
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered
pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which
registered
|
Common Stock, $0.01 Par Value
|
|
ABBV
|
|
New York Stock Exchange
Chicago
Stock Exchange
|
1.375% Senior Notes due 2024
|
|
ABBV24
|
|
New York Stock Exchange
|
0.750% Senior Notes due 2027
|
|
ABBV27
|
|
New York Stock Exchange
|
2.125% Senior Notes due 2028
|
|
ABBV28
|
|
New York Stock Exchange
|
1.250% Senior Notes due 2031
|
|
ABBV31
|
|
New York Stock Exchange
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 8.01.
|
Results of Operations and Financial Condition.
|
On May 8, 2020, AbbVie
Inc. (“AbbVie”) completed its acquisition of Allergan plc (“Allergan”).
Pursuant to the Transaction Agreement, dated as of June 25, 2019 (as amended on May 5, 2020), by and among AbbVie, Allergan and Venice
Subsidiary LLC, a Delaware limited liability company and a direct wholly-owned subsidiary of AbbVie (“Acquirer Sub”), Acquirer
Sub acquired Allergan pursuant to a scheme of arrangement (the “Scheme”) under Chapter 1 of Part 9 of the Irish Companies
Act 2014 (the “Act”) and a capital reduction under Sections 84 to 86 of the Act (the “Acquisition”). As
a result of the Scheme, Allergan became a wholly-owned subsidiary of AbbVie.
To partially fund the Acquisition, on November 21,
2019, AbbVie completed the private offering and issuance of senior unsecured notes in a combined aggregate principal amount
of $30 billion (the “2019 USD Notes”). Also, in connection with the Acquisition, on May 14, 2020, AbbVie
completed its offers to exchange (the “Exchange Offers”) any and all outstanding notes issued by certain
subsidiaries of Allergan for new notes issued by AbbVie. Upon settlement of the Exchange Offers, AbbVie issued (i)
approximately $13.7 billion in aggregate principal amount of senior unsecured notes (the “2020 USD Notes”) and
(ii) approximately €2.5 billion in aggregate principal amount of senior unsecured notes (the “Euro Notes”
and, together with the 2019 USD Notes and the 2020 USD Notes, the “Notes”). In accordance with the terms of the
registration rights agreements entered into in connection with the issuance of the Notes, AbbVie will offer to exchange in
registered exchange offers (the “Registered Exchange Offers”) certain series of the Notes for new notes (the
“Registered Notes”). The terms of the Registered Notes to be issued in the Registered Exchange Offers are
substantially identical to the terms of the corresponding series of Notes, except that the offering of the Registered Notes
will be registered under the Securities Act of 1933, as amended, and the transfer restrictions, registration rights and
additional interest provisions applicable to the Notes will not apply to the Registered Notes.
In
connection with the Registered Exchange Offers, AbbVie is filing this Current Report on Form 8-K in order to make available the
unaudited pro forma condensed combined financial information of AbbVie giving effect to the Acquisition (the “pro forma financial
information”), which includes the unaudited pro forma condensed combined statements
of earnings for the year ended December 31, 2019 and for the six months ended
June 30, 2020 and the related notes, and which is filed herewith as Exhibit 99.1 and included herein.
The
pro forma financial information included in this Current Report on Form 8-K has been presented for informational purposes only and
is not necessarily indicative of the combined financial position or results of operations that would have been realized had the
Acquisition occurred as of the dates indicated, nor is it meant to be indicative of any anticipated combined financial position
or future results of operations that AbbVie will experience after the Acquisition.
Item 9.01.
|
Financial Statements and Exhibits.
|
(b)
|
Pro Forma Financial Information.
|
The unaudited pro forma condensed
combined financial information of AbbVie, giving effect to the acquisition of Allergan, which includes the unaudited pro forma
condensed combined statements of earnings for the year ended December 31, 2019 and for the six months ended June 30, 2020 and the
related notes, is filed herewith as Exhibit 99.1 and included herein.
The following exhibits are
included as part of this Current Report on Form 8-K:
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ABBVIE INC.
|
|
|
Date: October 2, 2020
|
By:
|
/s/ Robert A. Michael
|
|
Name:
|
Robert A. Michael
|
|
Title:
|
Executive Vice President, Chief Financial Officer
|
Common Stock, $0.01 Par Value
|
ABBV
|
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Aug 2024 to Sep 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Sep 2023 to Sep 2024